Activity Description
This Annals of Surgical Oncology Journal CME/MOC activity consists of a journal article, a self-assessment exam, and an evaluation.
Authors
Alexander C. J. van Akkooi, MD, PhD, Tina J. Hieken, MD, Elizabeth M. Burton, MBA, Charlotte Ariyan, MD, PhD, Paolo A. Ascierto, MD, Salvatore V. M. A. Asero, MD, PhD, Christian U. Blank, MD, PhD, Matthew S. Block, MD, PhD, Genevieve M. Boland, MD, PhD, Corrado Caraco, MD, PhD, Sydney Chng, MBBS, PhD, FRACS, B. Scott Davidson, MD, Joao Pedreira Duprat Neto, MD, PhD, Mark B. Faries, MD, Jeffrey E. Gershenwald, MD, Dirk J. Grunhagen, MD, PhD, David E. Gyorki, MBBS, MD, FRACS, Dale Han, MD, Andrew J. Hayes, MBBS, PhD, Winan J. van Houdt, MD, PhD, George C. Karakousis, MD, MS, Willem M. C. Klop, MD, PhD, Georgina V. Long, BSc, PhD, MBBS, FRACP, FAHMS, Michael C. Lowe, MD, MA, FACS, FSSO, Alexander M. Menzies, MBBS, PhD, Roger Olofsson Bagge, MD, PhD, Thomas E. Pennington, BSc, MBBS, MS, FRACS, Piotr Rutkowski, MD, PhD, Robyn P. M. Saw, MBBS, MS, FRACS, Richard A. Scolyer, MBBS, MD, FRCPA, FRCPath, FAHMS, Kerwin F. Shannon, MBBS, FRACS, Vernon K. Sondak, MD, Hussein Tawbi, MD, PhD, Alessandro A. E. Testori, MD, Mike T. Tetzlaff, MD, PhD, John F. Thompson, FRACS, FACS, Jonathan S. Zager, MD, FACS, Charlotte L. Zuur, MD, PhD, Jennifer A. Wargo, MD, Andrew J. Spillane, MD, Merrick I. Ross, MD on behalf of International Neoadjuvant Melanoma Consortium (INMC)
Target Audience
This activity is intended for surgeons who are involved in the diagnosis, treatment, and management of patients with melanoma.
Learning Objectives
After completing this activity, participants will be able to:
- Discuss the current standard of care treatment landscape for stage III melanoma patients.
- Identify the potential benefits of neo-adjuvant systemic therapy (NAST) for stage III melanoma patients.
- Distinguish the differences between NAST and adjuvant systemic therapy for melanoma patients.
- Discuss the risks involved with NAST for stage III melanoma patients.
Accreditation
The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The Society of Surgical Oncology designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The SSO has approved this activity for up to 1 self-assessment credit which meets the requirement of the self-assessment component, Part II of the American Board of Surgery (ABS) Maintenance of Certification (MOC) Program.
Requirements for Earning Credit and Method of Participation
This online activity consists of an article, a self-assessment exam, and an evaluation. To receive AMA PRA Category 1 Credit™ and self-assessment credit, participants must watch the webinar, successfully complete the self-assessment exam, and achieve a minimum score of 75% on the exam. The self-assessment exam includes 4 multiple choice questions. Learners will be asked to read each question, select an answer, and review the section of the webinar where the answer is found. Learners will be able to review the content and repeat the self-assessment exam as many times as needed. Upon achieving a score of 75% or higher, learners will be asked to complete a post-activity evaluation. A certificate of credit or participation will be available upon successful submission of the post-activity evaluation.
Estimated Time to Complete Activity
The estimated time to complete this entire activity is 1 hour.
Release Date
April 27, 2022
Expiration Date
April 27, 2023
Disclosures
As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.
All identified conflicts of interest must be resolved, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.
All identified conflicts of interests have been resolved.
Planners, Reviewers, and Staff
Alexander van Akkooi, MD, Author: AMgen - Advisor, Research Grant; Bristol-Myers Squibb - Advisor; Novartis - Advisor; MSD-Merck - Advisor; Merck-Pfizer - Advisor, Research Grant; Pierre Fabre - Advisor; Sanofi - Advisor; Sirius Medical - Advisor; 4SC - Advisor
Rogerio Neves, MD, Disease Site Work Group Planner: Genentech/Roche - Consultant, Advisory Board; Novartis - Consultant, Advisory Board; Castle Biosciences - Consultant, Advisory Board, Research Grant; Sanofi/Genzyme - Consultant, Advisory Board; Regeneron Pharmaceuticals - Research Grant; Replimune - Research Grant
Laura Dominici, MD, Chair at the time of review, CME/CPD Committee, has disclosed no conflicts of interest.
Meghan Forster, MD, CME/CPD Committee Reviewer, has disclosed no conflicts of interest.
Deborah A. Whippen, Managing Editor, Annals of Surgical Oncology, has disclosed no financial relationships. (Planner/Staff)
Julie Smith, Editorial Manager, Annals of Surgical Oncology, has disclosed no financial relationships. (Planner/Staff)
Kelley Gazer, SSO Staff, has disclosed no financial relationships. (Planner/Staff)
Disclaimer
The primary purpose of the Society of Surgical Oncology's journal-CME is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.
Disclosure of Unlabeled Use
This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.
Privacy and Confidentiality